Savara Utdeling 2024

Hva gjør Savara?

Savara Inc is a US biotechnology company specializing in the development and commercialization of therapies for rare respiratory diseases. The company was founded in 2007 and is headquartered in Austin, Texas. Savara initially focused on treating cystic fibrosis, a genetic disease that can cause severe lung problems. The company developed an innovative therapy based on the use of liposomes, tiny bubbles that can deliver medication directly to the lungs. This method was considered promising and received orphan drug status from the FDA, meaning it is intended for the treatment of rare diseases. However, due to high costs associated with developing and approving a new medication for cystic fibrosis, Savara decided to redefine its goals and focus on other rare respiratory diseases. The company's business model is based on identifying promising therapy approaches for these diseases and developing them into approvable medications. Savara collaborates closely with leading experts and scientists in the field of respiratory diseases. Its main therapy areas include cystic fibrosis, pulmonary fibrosis, and rare lung diseases. Savara has a special focus on developing liposome-based therapies, which have the potential to target the affected areas in the lungs and enhance the effects of other medications. Currently, the company offers three products: - AeroVanc: A liposome-based inhaled antibiotic used to treat cystic fibrosis-induced chronic lung infections. AeroVanc is the first FDA-approved medication in Savara's history. - Molgradex: A recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) being developed for the treatment of autoimmune pulmonary alveolitis (also known as extrinsic allergic alveolitis). - AVAIL: A liposome-based inhaled antibiotic currently in Phase II of clinical development, being developed to treat non-tuberculous mycobacterial (NTM) lung infections. Savara has also formed partnerships with other companies and organizations to advance its research and development. Partners include the Cystic Fibrosis Foundation, the National Institutes of Health (NIH), and the European Respiratory Society. In summary, Savara Inc is a biotechnology company focused on developing therapies for rare respiratory diseases. The company has developed a promising technology platform and collaborates closely with leading experts and scientists in the field. Savara has a range of products on the market, including the first FDA-approved medication in the company's history. Savara er et av de mest populære selskapene på Eulerpool.com.